anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo a biopsy and receive standard of care neoadjuvant chemotherapy before undergoing surgery.
The embodiments herein disclose method and composition for the treatment of external fissures, internal fissures, constipation and tissue crack around anus. The herbal spray for external anal fissure comprises 32000mg of  Matricaria recutita  extract, l000mg of  Crocus sativus  extract, 7000mg of Aloe vera extract and 10000mg of  Althaea officinalis  flower extract. The herbal spray for internal anal fissure comprises 40000mg of  Matricaria recutita  flower extract, 25000mg  Allium porrum  shoot extract, 25000mg  Apium graveolens  stalk extract, 15000mg  Fumaria officinalis  shoot extract and 5000mg honey. The topical anti constipation oil mixture comprises 30000mg  Sesamum indicum  and 20000mg castor oil. The anus anti-crack ointment comprises 15000mg sesame oil, 8500mg olive oil and 1500mg  spermaceti . The external spray treats clots and bleeding. The internal herbal mixture stops bleeding, heals internal swelling, eases defecation and recovers rectum. The topical oil and anti-crack ointment softens the skin and helps the recovery of cracks inside the anus.
Delayed-release therapeutic compsn. comprises a powder of particle size 10 mu m, each particle being a grain of active component coated with a plastic film, insoluble in biological liquids and fats. The compsns are prepd. by dissolving the active component, the film-former and a fat in a common solvent, then co-pptg. the three components by spraying the soln, in very fine droplets on to a layer of a non-solvent for the 3 components. Suitable film formers are iso-butyl polymethacrylate or polyolefins such as Microthene FM 510. Fats include fatty acids, esters or polyoxyethyleneglycols.
Collecting representative and inclusive data about sexual orientation and gender identity (SOGI) is a critical component of combating the devastating health disparities affecting sexual and gender minority (SGM) older adults. This is particularly crucial for patients living with ADRD, which is widely regarded as a family disease requiring the active caregiver involvement, particularly with advanced disease. Failure to collect and integrate SOGI data to identify patients' informal support systems may have adverse health consequences for SGM older adults, particularly for those dependent on informal caregivers to provide in-home support and assist with activities of daily living. Improper identification of chosen family and caregivers contributes to incomplete care delivery and disenfranchised grief. Given the historical discrimination experienced by older SGM people, adding SOGI questions without proper training has the potential to harm patients and create staff discomfort rather than foster inclusive interactions. For this career development award, I propose to characterize SOGI data collection challenges from patients and caregivers enrolling in hospice while exploring understudied intersections, such as SGM people living with ADRD, and how they affect staff approaches to delivering person-centered care. These insights will be used to develop and pilot test an intervention to train hospice interdisciplinary team (IDT) staff to sensitively collect and utilize SOGI data to improve communication with SGM patients and caregivers.
Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease in adults affecting upper and lower motor neurons resulting in progressive muscle atrophy and paralysis of the patients within 2 to 5 years. The majority of ALS cases are sporadic (SALS), 5 to 10% are familial forms (FALS). In France, the most frequent mutation is an intronic hexanucleotide expansion in the C9orf72 gene, representing 46% of FALS followed by mutations in the first discovered ALS gene, SOD1 accounting for around 10% of FALS. Using mutant SOD1 ALS mouse models, the investigators and others have shown that motor neurons degenerated through a non-cell autonomous mechanism involving microglial cells. Microglial cells are the macrophages of the central nervous system (CNS) capable of producing neurotrophic or neurotoxic factors. Microglial cells are part of the myeloid lineage like macrophages at the periphery, however these two cell types have different developmental origins and are in different environments. Spinal motor neurons are particular neurons since their cell body is in the CNS, and therefore surrounded by microglial cells, while their axon extends at the periphery and is therefore in contact with peripheral macrophages. The investigators have shown that (i) peripheral macrophages in affected peripheral nerves of ALS mouse models and ALS patient post-mortem tissues were activated, (ii) in ALS mouse models, both microglial cells but also peripheral macrophages participated in disease progression and (iii) peripheral macrophages were able to influence microglial cell reactivity.

The working hypothesis is that peripheral macrophages are themselves (and not just microglial cells) involved in ALS and with this project the investigators want to compare macrophages from ALS patients and controls using macrophages derived from blood monocytes. The aim is to analyze the macrophage transcriptome and protein markers of Amyotrophic Lateral Sclerosis (ALS) patients compared to controls (non-affected individuals, patients with other motor impairments) and asymptomatic ALS gene carriers, to find new pathways to target and disease biomarkers.
The invention belongs to the technical field of medicine, and provides curcumol liposome and a preparation method thereof. The curcumol liposome is liposome or precursor liposome prepared from curcumol, phospholipids, cholesterol and other auxiliary materials, wherein antioxidant, organic acids, alkali, sugar, buffer and other auxiliary materials can also be added. Phospholipids as membrane material can adopt the prior phospholipids products on the market, including naturally extracted phospholipids, semi-synthetic or fully synthetic phospholipids or mixture thereof, and the quantity ratio of phospholipids to pharmaceutical substances is between 1.5:1 and 50:1. The preparation method can adopt an ethanol injection method, a thin-film dispersion method, a reverse evaporation method, an extrusion method, a mechanical method and the like. The ratio of supporting agent to the phospholipids is between 0.001:1 and 100:1. The curcumol liposome can be used for preparing anti-tumor medicaments for treating gastric cancer, liver cancer, cervical cancer and the like, and has the advantages of good stability, high encapsulation efficiency, low cost and few toxic-side effects. The preparation method is easy in process.
The invention provides a medical application of tricholoma matsutake high-yield strain (T35) in resisting fatigue. Tricholoma matsutake high-yield strain powder is prepared through liquid submerged fermentation, centrifugalization and drying, and ethological experiments verify that the tricholoma matsutake high-yield strains have an obvious fatigue resisting effect. The method of the medical application is simple. The high-yield strain is remarkable in fatigue resisting effect, free of toxic and side effects, low in cost, and widely applicable to development and preparation of anti-fatigue series health care products, food and medicine as a medical fungus. The tricholoma matsutake is obtained through submerged liquid fermentation, and does not need to be extracted from natural medical materials, so that the limit of wild resource insufficiency is broken. Besides, the tricholoma matsutake high-yield strain is safe and effective and has a quite good industrial application prospect.
PSD-95/SAP90 antisense-treated animals not only experience a significant decrease in MAC for isoflurane, but also experience an attenuation in the NMDA-induced increase in isoflurane MAC. PSD-95/SAP90 appears to mediate the role of the NMDA receptor in determining the MAC of inhalational anesthetics. Suppression of the expression of PSD-95/SAP90 in the spinal cord significantly attenuates responses to painful stimuli mediated through the N-methyl-D-aspartate receptor activation. In spinal cord neurons PSD-95/SAP90 interacts with the N-methyl-D-aspartate receptor subunits 2A/2B. Activation of the N-methyl-D-aspartate receptor in spinal hyperalgesia results in association of the N-methyl-D-aspartate receptor with PSD-95/SAP90. PSD-95/SAP90 is required for hyperalgesia triggered via the N-methyl-D-aspartate receptor at the spinal cord level.
FIELD: medicine. ^ SUBSTANCE: invention refers to cosmetic industry. Application of 4-alkyloxazolidine-2-one as a moisturising cosmetic agent for making a moisturising cosmetic composition. A cosmetic procedure for rendering a moisturising effect, involving application of the moisturising agent 4-alkyloxazolidine-2-one on a skin area requiring the moisturising treatment. ^ EFFECT: product is effective as a moisturising agent. ^ 10 cl, 3 ex
A drug delivery device is provided that includes a device body, a number of solid, compressed drug tablets, and a retention frame. The device body includes a drug reservoir lumen and a retention frame lumen. The number of solid, compressed drug tablets are positioned in the drug reservoir lumen, and the retention frame is positioned in the retention frame lumen. The drug tablets may be mini-tablets aligned in the drug reservoir lumen, with an interstice formed between any two adjacent drug tablets facilitating deformation of the device body. Systems and method are also provided for loading a drug delivery device. In one embodiment, the method includes positioning one or more solid drug units upstream of the drug delivery device; and driving the drug units into the drug delivery device with a flow of pressurized gas.
Fesoterodine fumarate extended-release tablets contain fesoterodine fumarate and are an extended-release tablet for oral administration. Fesoterodine is rapidly de-esterified to its active metabolite (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, or 5-hydroxymethyl tolterodine, which is a muscarinic receptor antagonist.

Chemically, fesoterodine fumarate is designated as isobutyric acid 2-((R)-3-diisopropylammonium-1‑ phenylpropyl)-4-(hydroxymethyl) phenyl ester hydrogen fumarate. The empirical formula is C30H41NO7 and its molecular weight is 527.66. The structural formula is:

The asterisk (*) indicates the chiral carbon.

Fesoterodine fumarate is a white to off-white powder, which is freely soluble in water. Each fesoterodine fumarate extended-release tablet contains either 4 mg or 8 mg of fesoterodine fumarate and the following inactive ingredients: colloidal silicon dioxide, glyceryl behenate, hypromellose, lactose monohydrate, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. The 8 mg tablet also contains red iron oxide, yellow iron oxide and black iron oxide.
Methods and compositions for modulating apoptosis in cells and patients are provided. One method comprises selecting a compound which affects the formation of large channels comprised of multiple molecules of a pro-apoptotic member of the BCL-2 family, then administering the compound to the cell or patient. Another method comprises selecting a compound which affects the formation of a channel that includes at least four molecules of a pro-apoptotic BCL-2 family member polypeptide, then administering the compound to the cell or patient. Compounds which affect these channel characterictics are also provided. Additionally, methods for identifying apoptosis-modulating compounds using lipid membranes are provided. One method involves contacting a compound of interest with a lipid membrane which contains an ion-channel formed by an anti-apoptotic or pro-apoptotic polypeptide of the BCL-2 family and assaying for changes in the size of the pore. Changes in ion conductance properties of the channel, including ion selectivity, the ability to allow the passage of cytochrome c and/or FD10, single channel conductance and rectification are also useful characteristics for identifying apoptosis-modulating compounds.
The invention relates to external medicinal liquor for curing psoriasis, belonging to the traditional Chinese medicine field. The external medicinal liquor is characterized in that: the raw material medicine making active ingredients of the medicinal liquor by weight is: 10 grams of coralbean bark, 100 grams of chaulmoogra, 100 grams of fructus cnidii selinum, 90 grams of radix sophorae flavescentis and 30 grams of camphor. The raw material medicine is porphyrized, placed into a container and then added with 500 milliliters of distilled spirit to be immersed for 10 days, and then the process is completed after filtration and deslagging. The external medicinal liquor plays a part in itch removal, antipyresis and toxin expelling. The external medicinal liquor begins from the pathogenic causes of psoriasis patients and recovers the immunity function of the psoriasis patients. The external medicinal liquor is particularly suitable for various stubborn diseases which can not be cured for a long time and patients who suffer from repeated attack after stopping taking medicine, and is characterized by short treatment period, quickness in taking effect, recurrence resistance, no toxic side effect and so on. As shown by clinical verification, the itch is removed after taking the external medicinal liquor for 7 days and the cortex is softened after taking the external medicinal liquor for 15 days; and general patients only need two to four treatment periods. The effectiveness ratio of the external medicinal liquor is 100 percent and the cure rate of the external medicinal liquor is 97.6 percent.
<P>PROBLEM TO BE SOLVED: To provide a water-in-oil emulsifier type external preparation for skins, which can be used even in summer.  <P>SOLUTION: This water-in-oil emulsifier type external preparation for the skins is characterized by containing (1) an organic modified clay mineral and (2) a branched fatty acid. The organic modified clay mineral is preferably distearodimonium-modified hectrite, and the branched fatty acid is preferably isostearic acid. It is preferable to furthermore contain an amphoteric metal oxide or hydroxide. It is preferable that the amphoteric metal oxide or hydroxide is zinc oxide.  <P>COPYRIGHT: (C)2009,JPO&INPIT
FIELD: biotechnology, microbiology. SUBSTANCE: invention relates to preparing producers used for producing probiotic preparations - bacteritic preparations based on live cultures of microorganisms-symbionts used for prophylaxis and treatment of dysbacteriosis and other disorders of gastroenteric tract. Method involves insertion of nonconjugative nonmobilized plasmid pColap carrying genes encoding colicin E1 and factor that determines resistance to ampicillin (doses up to 150 mg/l) into the strain Escherichia coli M17 - producer used for preparing probiotic preparation coli-bacterin. Obtained strain has no nondesirable adhesive phenotype by inactivation of adhesive gene fim H pili of the 1-st type by integration of resistance gene npt to kanamycin-neomycin. The strain E. coli M17 fim H::can/p Colap is deposited in VKPM at N B-7448. Invention ensures to obtain the probiotic preparation showing decreased capacity to colonization and distinct from interstitial niches, increased antagonistic activity and showing residence on the background of therapy with antibiotics carrying out. Traits inserted into the constructed strain are conserved stably. This approach alleviates preparing the standard preparation based on the strain and prevents elimination of plasmid if the preparation is intaken by patient without the accompanying therapy with antibiotics. EFFECT: strain indicated above, valuable properties and traits. 4 dwg, 1 tbl, 3 ex
The invention discloses a cefoperazone sodium compound and a sulbactam sodium compound. The cefoperazone sodium compound and the sulbactam sodium compound are both prepared with a strong-field coupling crystallization technology, specifically, ultrasonic out-field strengthened crystals are added in the compound crystallization process, and the high-purity compounds are prepared. 'Research & Development of the Industrialization Project of High-end Medicine Product Refining Crystallization Technologies' wins the 2015 national scientific and technological progress second prize, and the high-field coupling crystallization technology belongs to one of high-end medicine product refining crystallization technologies. The two compounds have the characteristics of high purity and good stability. Besides, the invention further discloses cefoperazone sodium and sulbactam sodium medicinal composition. The cefoperazone sodium and sulbactam sodium medicinal composition is prepared from components in parts by weight as follows: 0.25-2 parts of cefoperazone sodium (on the basis of C25H27N9O8S2) and 0.25-2 parts of sulbactam sodium (on the basis of C8H11NO5S).
The present invention provides methods and compositions for modulating transendothelial migration (TEM) of leukocytes. In particular, inhibition of TEM can provide a potent therapeutic approach to treating inflammatory conditions. The invention specifically relates to the discovery that the adhesion molecule CD99L2 mediates TEM of leukocytes. CD99L2 is present on endothelial cells and leukocytes and mediates leukocyte-endothelial cell adhesion. Blockade of CD99L2 by use of a specific antibody blocks migration of leukocytes into a site of inflammation. CD99L2 shows functional analogy to the structurally-related molecule, CD99, inhibition of which, in conjunction with inhibition of PECAM, causes near total blockade of TEM. Thus, blocking CD99L2 on either endothelial cells or monocytes can block migration 80-90%. In conjunction with PECAM inhibitors, TEM blockade can approach 100%. Therapeutic treatments involving inhibition of CD99L2 show significant promise in remediation of inflammatory conditions.
Status gelasticus is a rare form of status epilepticus characterized by prolonged and/or clustered gelastic seizures. The review encompasses an analysis of cases reported in the literature, focusing on causes, clinical-electroencephalographic features, and therapeutic interventions. The study reveals the challenges in defining and understanding status gelasticus due to its diverse etiologies and limited reported cases. The association with hypothalamic hamartomas and other brain abnormalities underscores the importance of thorough evaluations. The review also discusses new treatments, including medications and less invasive surgeries. While progress has been made, the study points out challenges in diagnosing and managing this complex condition, highlighting the importance of ongoing research.
Methamphetamine is a powerful stimulant that affects the central nervous system. Chronic methamphetamine use often leads to psychotic behavior. Rivastigmine is an acetylcholinesterase inhibitor that is currently approved to treat Alzheimer's-related dementia. The purpose of this study is to assess the efficacy of rivastigmine in treating methamphetamine dependent individuals.

Participants will be randomly assigned to either one of two dose levels of rivastigmine or placebo for 12 weeks. Participants will be assessed for cardiovascular, subjective, and reinforcing effects that are produced by methamphetamine. All participants will partake in contingency management sessions through Week 4.
Eligible participants were randomized to either NAC (2400 mg/day) or placebo for 8 weeks. The starting dose of NAC was 1200 mg twice daily (2400 mg/day). All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance.
BACKGROUND: The osteonecrosis ratio in valgus impacted fractures of the proximal humerus is low (<10 %), giving osteosynthesis all its meaning. However, the optimal fixation technique remains controversial. After recentering the humeral head, osteosuture is stable enough to allow bone healing in an adequate position as well as a good long-term shoulder functionality.
METHODS: Our cohort included 22 patients with a mean age of 65 (28-83). Patients were placed in a beach-chair position. Surgical exposure was done through an anterolateral, transdeltoid approach. Stay sutures were placed on both tuberosities. Elevation of the humeral head was obtained for 9 patients using iliac crest bone graft, for 7 patients using bone substitutes, for 6 without any graft needed. Both tuberosities were approximated and tied together using two horizontal non-absorbable double-threaded sutures. The whole head was also tied to the humeral metaphysis by cerclage wiring using the same suture. Patients were immobilized in a sling for 4 weeks with no passive or active mobilization; then began rehabilitation starting with passive and active-assisted mobilization. Functional outcome was assessed with the Constant score. Radiographic follow-up was used for fracture healing and osteonecrosis signs.
RESULTS: All fractures united within the first 3 months. One patient had radiographic signs of osteonecrosis and one had a secondary displaced fracture without osteonecrosis. At an average follow-up of 35 months, the median Constant score was 83.7 % (63-100) in comparison to the uninjured side.
DISCUSSION: A preserved posteromedial periosteal hinge in a valgus impacted fracture of the proximal humerus is key to the success of osteosuture. This hinge provides mechanical stability to the humeral head once elevated, as well as blood-supply from the branches of the posterior circumflex humeral artery. Computed Tomography with Three-Dimensional reconstructed images allow for a precise analysis of this hinge as well as the vascularity of the humeral head. Osteosuture being a minimally invasive surgical procedure plays a predominant role in sparing the remaining vascularization of the humeral head.
CONCLUSION: Osteosuture in four-part valgus impacted fractures of the proximal humerus is a minimally invasive procedure as well as a reliable technique yielding good long-term results.
The study period is 16 weeks which contains a 12-week treatment effect evaluation period and 4-week safety follow up. The primary objective is to evaluate the safety of Xolair® in a real-world setting in Chinese adolescent patients with Chronic Spontaneous Urticaria who remain symptomatic despite H1 antihistamine treatment over a 16-week study period. The secondary objectives are to evaluate the effectiveness (measured by ISS7, UAS7, UCT) of Xolair® and the quality of life (measured by CDLQI) of Chinese adolescent patients over a 12-week treatment period. Data will be collected in conjunction with routine care visits at the site, at Week 4, 8, 12 (recommended scheduled visits). Routine clinical assessments will be conducted, and safety information will be collected. Safety information includes AE/SAE collection, including but not limited to lab tests, vital signs, weight, physical examination etc. No extra study visits, examinations, laboratory tests or procedures other than activities performed in clinical practice will be mandated.